LSIPR 50 2018: The entrepreneurial bug
18-07-2018
Flamingo Images / Shutterstock.com
Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.
The strength of a company’s IP is a central factor in determining its value, and perhaps nowhere is this more evident than in the life sciences industry. Because of the huge upfront expenditures required to develop products in the pharmaceutical, biotechnology, and other life sciences industries, a strong IP portfolio can be the difference between success and failure.
Life sciences entrepreneurs often face different IP challenges from those in other industries due to long product life cycles and expensive research and development (R&D), among other concerns.
Long product life cycles
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Fish & Richardson, entrepreneurs, IP portfolio, pharmaceuticals, biotechnology, life sciences, R&D, patent protection, investment, FDA, infringement
